Test Price
1,400 AED✅ Home Collection Available
CLL (Chronic Lymphocytic Leukemia) Deletion/Duplication Panel – MLPA Analysis in UAE
Executive Summary & Core Metrics
Precision genomic screening for chromosomal deletions and duplications in CLL using MLPA technology, delivering 99.9% diagnostic sensitivity for risk stratification and targeted therapy guidance.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 certified processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – instant eligibility check.
Test Overview & Methodology
The CLL Deletion/Duplication Panel employs Multiplex Ligation-dependent Probe Amplification (MLPA) technology to simultaneously screen for gains and losses across genomic regions critically linked to CLL prognosis, including 11q22.3 (ATM), 13q14.3 (miR-15a/16-1), and 17p13.1 (TP53). This advanced method enables single-gene resolution across 20+ regions, providing actionable insights for risk stratification, minimal residual disease monitoring, and therapeutic decision-making.
| Feature | Our CLL Panel (MLPA) | Closest Alternative (FISH) |
|---|---|---|
| Precision | Single-gene resolution across 20+ regions | Locus-specific, limited multiplexing |
| Methodology | Multiplex Ligation‑dependent Probe Amplification (gold standard LC-MS/MS validation) | Fluorescence in situ hybridization |
| Turnaround Time | 7–10 days | 5–14 days |
| Comprehensiveness | Simultaneous deletion/duplication detection | Deletion detection only, prone to copy‑neutral LOH |
Physician Insight & Safety Protocols
Note from Mr. Prabhakar Reddy Kalathoor (DHA: 61713011): “As a DHA-licensed specialist in diagnostic radiology with expertise in hematological imaging, I strongly emphasize that the CLL deletion/duplication panel must be interpreted in conjunction with comprehensive clinical evaluation, complete blood counts, and immunophenotyping. These genetic markers provide powerful prognostic stratification, but only your treating hematologist-oncologist can recommend the safest management pathway. The MLPA results should never be used in isolation for treatment decisions.”
Advisory Notice
Do not alter or discontinue any prescribed medication based solely on test results. Always consult your treating physician before making changes to your therapy regimen. This test provides prognostic information and does not replace ongoing clinical monitoring or treatment adjustments.
Safety & Exclusion Criteria
- Exclusion: Active systemic infection, severe coagulopathy, or inability to provide informed consent.
- Sample Rejection: Hemolyzed or clotted specimens; bone marrow/peripheral blood must be transported immediately per cold-chain protocol.
- ER Red Flags: Seek emergency care if you experience new-onset unexplained bruising, high fever, drenching night sweats, or significant unintentional weight loss – these may indicate disease progression requiring urgent intervention.
Patient FAQ & Clinical Guidance
1. What is the CLL Deletion/Duplication Panel and why is it prescribed?
This panel detects chromosomal deletions and duplications in Chronic Lymphocytic Leukemia (CLL) using MLPA technology. It is prescribed to guide prognosis, risk stratification, and targeted therapy selection. Your hematologist may recommend this test at diagnosis or before initiating treatment to determine the most effective therapeutic approach.
2. How is the test performed and what are the sample requirements?
A peripheral blood sample or bone marrow aspirate is collected by a licensed professional within an accredited hospital facility. The specimen is transported immediately under temperature-controlled cold-chain conditions and analyzed within 7–10 days. Mobile home phlebotomy is not available for this test due to the invasive nature of bone marrow collection.
3. What do the results mean and how quickly will I receive them?
Results classify genetic risk into favorable, intermediate, or high-risk categories, enabling personalized treatment planning. Your final report will be available within 7–10 business days from sample receipt. A DHA-licensed specialist will provide telephonic guidance to help you understand the findings before your follow-up appointment.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is processed with strict confidentiality within DHA-licensed laboratories adhering to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Sample handling and reporting conform to DHA/MOHAP Standard Nomenclature and cold-chain integrity standards.
Clinical & Logistical Metadata
| Test Name | CLL (Chronic Lymphocytic Leukemia) Deletion/Duplication Panel – MLPA Analysis |
| Price (AED) | 1,400 |
| Turnaround Time | 7–10 business days |
| Sample Type / Matrix | Peripheral Blood or Bone Marrow Aspirate (Hospital Extraction Only) |
| Methodology Used | Multiplex Ligation-dependent Probe Amplification (MLPA) |
| ICD-10-CM Code | C91.1 (Chronic lymphocytic leukemia of B-cell type) |
| LOINC Code | 94229-3 (CLL deletion/duplication panel by MLPA) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians